Last reviewed · How we verify

APG-1252

Ascentage Pharma Group Inc. · Phase 1 active Small molecule ✓ Verified May 2026

APG-1252 is a Bcl-2/Bcl-xL inhibitor Small molecule drug developed by Ascentage Pharma Group Inc.. It is currently in Phase 1 development for Solid tumors. Also known as: APG-1252 for injection, Pelcitoclax.

APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells.

APG-1252 is a small molecule being studied in clinical trials for various conditions, including Small Cell Lung Cancer and Other Solid Tumors, Myelofibrosis, Small Cell Lung Cancer, Advanced Endometrial Carcinoma, and Metastatic Endometrial Carcinoma. The safety, pharmacokinetic, and pharmacodynamic properties of APG-1252 are being evaluated in a Phase I study.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAPG-1252
Also known asAPG-1252 for injection, Pelcitoclax
SponsorAscentage Pharma Group Inc.
Drug classBcl-2/Bcl-xL inhibitor
TargetBcl-2, Bcl-xL
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 1

Mechanism of action

APG-1252 selectively binds to Bcl-2 and Bcl-xL proteins, disrupting their anti-apoptotic function and leading to the activation of caspases and subsequent cell death in tumor cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about APG-1252

What is APG-1252?

APG-1252 is a Bcl-2/Bcl-xL inhibitor drug developed by Ascentage Pharma Group Inc., indicated for Solid tumors.

How does APG-1252 work?

APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells.

What is APG-1252 used for?

APG-1252 is indicated for Solid tumors.

Who makes APG-1252?

APG-1252 is developed by Ascentage Pharma Group Inc. (see full Ascentage Pharma Group Inc. pipeline at /company/ascentage-pharma-group-inc).

Is APG-1252 also known as anything else?

APG-1252 is also known as APG-1252 for injection, Pelcitoclax.

What drug class is APG-1252 in?

APG-1252 belongs to the Bcl-2/Bcl-xL inhibitor class. See all Bcl-2/Bcl-xL inhibitor drugs at /class/bcl-2-bcl-xl-inhibitor.

What development phase is APG-1252 in?

APG-1252 is in Phase 1.

What are the side effects of APG-1252?

Common side effects of APG-1252 include Neutropenia, Thrombocytopenia.

What does APG-1252 target?

APG-1252 targets Bcl-2, Bcl-xL and is a Bcl-2/Bcl-xL inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing